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Abstract
Background: Phosphorylation of non-muscle myosin II regulatory light chain (RLC) at Thr18/Ser19 is well
established as a key regulatory event that controls myosin II assembly and activation, both in vitro and in living
cells. RLC can also be phosphorylated at Ser1/Ser2/Thr9 by protein kinase C (PKC). Biophysical studies show that
phosphorylation at these sites leads to an increase in the Km of myosin light chain kinase (MLCK) for RLC, thereby
indirectly inhibiting myosin II activity. Despite unequivocal evidence that PKC phosphorylation at Ser1/Ser2/Thr9
can regulate myosin II function in vitro, there is little evidence that this mechanism regulates myosin II function in
live cells.
Results: The purpose of these studies was to investigate the role of Ser1/Ser2/Thr9 phosphorylation in live cells. To
do this we utilized phospho-specific antibodies and created GFP-tagged RLC reporters with phosphomimetic
aspartic acid substitutions or unphosphorylatable alanine substitutions at the putative inhibitory sites or the
previously characterized activation sites. Cell lines stably expressing the RLC-GFP constructs were assayed for
myosin recruitment during cell division, the ability to complete cell division, and myosin assembly levels under
resting or spreading conditions. Our data shows that manipulation of the activation sites (Thr18/Ser19) significantly
alters myosin II function in a number of these assays while manipulation of the putative inhibitory sites (Ser1/Ser2/
Thr9) does not.
Conclusions: These studies suggest that inhibitory phosphorylation of RLC is not a substantial regulatory
mechanism, although we cannot rule out its role in other cellular processes or perhaps other types of cells or
tissues in vivo.
Background
Non-muscle myosin II is expressed in nearly every
eukaryotic cell, where it plays critical roles in a number
of cellular processes, including cell division and cell
migration. Myosin II molecules are comprised of two
heavy chains (MHC), two essential light chains (ELC)
and two regulatory light chains (RLC). The MHC con-
sists of a globular head domain that contains that actin
binding and ATPase properties, a linker region that con-
tains the binding sites for the ELC and RLC and a
coiled-coil rod domain that allows the MHC to dimerize
and assemble into bipolar filaments. Myosin II is in
constant equilibrium between monomeric and filamen-
tous forms. The cell achieves spatio-temporal control of
myosin II assembly and activation by modulation of this
equilibrium, primarily through phosphorylation events.
There are two groups of residues on the RLC that are
phosphorylated by distinct kinases and have contrasting
effects on myosin II biophysical properties. The first
group is Thr18/Ser19. Theser e s i d u e sa r ep h o s p h o r y -
lated by myosin light chain kinase, Rho kinase and
others [1]. Phosphorylationa tT h r 1 8 / S e r 1 9i saw e l l -
established regulatory mechanisms that increases the
actin-activated ATPase activity of the holoenzyme and
shifts the molecule into a filamentous state [2,3]. There-
fore, Thr18/Ser19 phosphorylation essentially “activates”
the myosin molecule to produce force. The second
g r o u po fp h o s p h o r y l a t e dr e s i d u e si sa tt h eN - t e r m i n u s
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have been shown to be phosphorylated by PKC [5]. Bio-
physical studies showed that PKC phosphorylation leads
t oa9 - f o l di n c r e a s ei nt h eK mo fM L C Kf o rR L C ,
thereby indirectly favoring a less active state for the
myosin II itself [6]. Further in vitro studies with Xeno-
pus myosin II using alanine substitution at either Ser1/
Ser2 or Thr9 followed by PKC pre-phosphorylation of
the remaining non-mutated residue identified Thr9 as
the critical inhibitory phosphorylation event [7].
Live cell studies showed that phosphorylation at Ser1/
Ser2 (but not Thr9) is elevated 6-12 fold higher in cells
arrested in mitosis versus non-mitotic cells [8]. Release
of the cells from mitotic arrest results in a decrease in
Ser1/Ser2 phosphorylation over the next hour, as the
cells progress through cell division [8]. These studies
support the hypothesis that “inhibitory” phosphorylation
at Ser1/Ser2, and perhaps Thr9, is a mechanism by
which the contractile machinery for cell division is held
in an inactive form during metaphase then activated
after the metaphase/anaphase transition. One recent
study identified elevated Ser1 phosphorylation in fibro-
blasts following treatment with platelet-derived growth
factor (PDGF) [9], concordant with disassembly of acto-
myosin stress fibers. Based on visual scoring, stress fiber
disassembly was reported to be attenuated with expres-
sion of an un-phosphorylatable RLC at Ser1/Ser2 [9].
However, aside from this single report, no studies have
addressed the importance of Ser1/Ser2/Thr9 phosphory-
lation in live cell settings.
The goal of our studies was to quantify the effect of
RLC inhibitory phosphorylation at Ser1/Ser2/Thr9 on
myosin II activity and assembly in live cells in multiple
settings. Utilizing phospho-specific antibodies and GFP-
tagged RLC constructs with mutations at the putative
activating and inhibitory sites, we find clear modulatory
roles for Thr18/Ser19 phosphorylation. However, our
data is inconsistent with the hypothesis that Ser1/Ser2/
Thr9 phosphorylation significantly regulates myosin II
function in live cells in the settings of cytokinesis or cell
spreading.
Results and Discussion
Using a phospho-specific antibody to RLC Ser1, we
immunostained HeLa and primary human keratinoctyes
under normal growth conditions. In agreement with
published reports [8,10], RLC Ser1 phosphorylation is
dramatically enhanced in mitotic cells (Figure 1A). The
previous study by Yamakita and colleagues examined
RLC phosphorylation following a semi-synchronous
release from mitotic arrest in metaphase. In doing so
they observed that Ser1/Ser2 phosphorylation decreased
as the cells progressed through mitosis. However, it is
not clear if the residual Ser1/Ser2 phosphorylation in
their “released” cells was in cells that had not yet transi-
tioned in to anaphase or in cells that were in anaphase.
To determine if RLC remains phosphorylated at Ser1 in
cells that are actively dividing, we imaged HeLa cells in
the anaphase state. In doin gs o ,w eo b s e r v e dt h a tR L C
Ser1 phosphorylation is enhanced specifically in the
contractile ring of anaphase cells (Figure 1B). This was
also true in primary human keratinocytes (Figure 1B,
bottom row). The Ser1-P antibody also strongly localizes
to peri-chromosomal regions in the HeLa cell line but
not the primary keratinocytes. As we never observe
endogenous RLC or MHC localizing to these areas (data
not shown) this peri-chromosomal staining either repre-
sents a very small percentage of the total myosin II in
the cell or it represents spurious antibody reactivity with
something other than the RLC.
It appears contradictory that myosin II is phosphory-
lated at putative inhibitory sites in the contractile ring,
where myosin II activity is proposed to be the dominant
force contributing to furrow ingression. However, inhi-
bitory phosphorylation and activated myosin II in a spe-
cific local, such as the contractile ring, may not be
mutually exclusive. In Dictyostelium discoideum, myosin
II disassembly is necessary for efficient completion of
cytokinesis [11]. Similarly, it may be that in mammalian
cells, RLC inhibitory phosphorylation contributes to dis-
assembly of myosin II in the contractile ring as the fur-
row ingresses.
To determine if modulation of the putative inhibitory
residues would alter myosin II behavior during cell divi-
sion, we created GFP-tagged RLC constructs with non-
phosphorylatable alanine substitutions (RLC-4A) and
phosphomimetic aspartic acid substitutions (RLC-4D) at
Ser1/Ser2/Thr9/Thr10. Thr10 was previously shown to
be a secondary phosphorylation site when Thr9 is
mutated [7], so this residue was also mutated in all con-
structs. As controls, we also created non-phosphorylata-
ble (RLC-T18A/S19A) and phosphomimetic (RLC-
T18D/S19D) mutations at the activation sites. These
constructs, along with the wild type RLC-GFP, were sta-
bly transfected into tetracycline-responsive HeLa cells,
allowing temporally regulated expression of the mutated
RLC-GFP proteins to avoid any chance of compensatory
background changes or adaptation in cells carrying
mutant constructs. When induced, these constructs
expressed at slightly higher levels than the endogenous
RLC and oftentimes appear to suppress expression of
the endogenous RLC (Figure 2A), presumably resulting
in a higher replacement of exogenous RLC on the myo-
sin II molecule. Note that the RLC antibody used
appears to have a lower affinity for the RLC-4A con-
struct. To further quantitate the percent replacement of
RLC-GFP for endogenous RLC we performed immuno-
precipitation of MHC IIA followed by western blotting
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Page 2 of 10(Figure 2B). Unfortunately, the IgG heavy chain co-
migrates with the RLC-GFP constructs, preventing any
ratio analysis of RLC:RLC-GFP. Use of a mouse primary
antibody for the IP followed by a rabbit antibody for
western blotting or use of immuno-depleted secondary
antibodies did not alleviate this problem. However, we
were able to ratio the endogenous RLC to the amount
of MHC IIA immunoprecipitated. Under the assumption
that the remaining MHC IIA is occupied with RLC-GFP,
we estimate our percent replacement to be ~80-95%.
To determine if mutations at the putative inhibitory
sites altered the ability of myosin II to localize to and
assemble in the furrow during cell division, we stained
HeLa cells for the most abundant MHC isoform, MHC
Figure 1 RLC Ser1 phosphorylation is elevated in mitotic cells and localizes to the contractile ring. (A) HeLa and primary human
keratinocytes (PHK) under normal growth conditions were fixed and immunostained for RLC Ser1-P (green) and stained for actin (red). (B) RLC
Ser1-P is specifically enhanced in the contractile ring of dividing cells.
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Page 3 of 10IIA. Recruitment of myosin II to the furrow was
assessed by fluorescent microscopy (Figure 2C), and
quantitated by normalizing peak cortical furrow signal
to cytoplasmic signal in a number of cells (Figure 2D).
Relative to expression of wild type RLC, expression of
RLC-T18A/S19A resulted in a decrease in the amount
of cortically assembled myosin II in the furrow (Figure
2C &2D). In contrast, expression of RLC-T18D/S19D
resulted in a relative overassembly of myosin II in the
furrow (Figure 2C &2D). If phosphorylation of RLC at
Ser1/Ser2/Thr9 inhibits myosin II assembly during cyto-
kinesis, then expression of RLC-4D should result in a
decrease in myosin II cortical signal in the furrow. This
does not appear to be the case (Figure 2C &2D). In fact
furrow recruitment was slightly elevated in this setting.
Furthermore, myosin II cortical assembly in RLC-4A
expressing cells was statistically indistinguishable from
wild type RLC expressing cells. This data suggests that
phosphorylation of Ser1/Ser2/Thr9 does not alter myo-
sin II assembly levels in the contractile ring.
Figure 2 Expression, localization and assembly of MHC IIA during cell division. (A) Whole cell lysates of HeLa cells expressing the indicated
RLC construct were probed for total RLC, GFP and MHC IIA. (B) MHC IIA was immunoprecipitated from the indicated cell line and the eluate was
probed for MHC IIA, RLC and GFP. Note that the RLC-GFP and IgG heavy chain migrate too close to differentiate. The number under each
construct indicates the relative amount of RLC present after normalization to MHC IIA based on densitometry. (C) Anaphase cells expressing the
indicated RLC construct (green) were fixed and stained for MHC IIA (red). Representative images are shown. (C) MHC IIA recruitment was
quantitated for a minimum of 13 cells. Data are mean +/- SEM. * indicates p = < 0.003.
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Page 4 of 10Note that the RLC-GFP constructs often localize to
the spindle independent of the MHC (Figure 2C). We
do not see this spindle localization when we immunos-
tain for endogenous RLC protein (data not shown). This
spindle localization appears to be different than the
peri-chromosomal staining seen with the Ser1-P anti-
body (Figure 1B). Therefore, these appear to be indepen-
dent anomalies from as of yet unknown origins.
It remains possible that phosphorylation at Ser1/Ser2/
Thr9 may alter myosin II activity during cell division,
resulting in an altered rate of furrow ingression. To
investigate this, we measured furrow ingression rates of
dividing cells expressing each of the RLC constructs
(Figure 3A). The only cells that consistently had a statis-
tically significant slower furrow rate relative to wild type
were the cells expressing RLC-T18A/S19A. Surprisingly,
even these cells were able to complete furrow ingression
and divide successfully, similar to previous reports [12].
Furthermore, analysis of nucleation state as an indicator
of multinucleation revealed that none of the RLC
mutant constructs induced a multinucleation phenotype
(Figure 3B). The myosin II inhibitor blebbistatin did
cause a significant shift into a multinucleated state, indi-
cating an absolute necessity for myosin II activity (Fig-
ure 3B). Similar results were obtained in HEK293 cells
(data not shown). In summary, our data suggests that
modulation of the RLC activating sites (Thr18/Ser19)
clearly impacts myosin II recruitment to the furrow, but
has modest effects on furrow rates, and no detectable
effect on completion of furrowing as assessed by
multinucleation. Phosphomimetic substitution of the
putative inhibitory sites (Ser1/Ser2/Thr9) on RLC con-
ferred an effect on assembly opposite of what would be
predicted if these sites are inhibitory and had little or
no effect on furrow rates. Alanine substitutions at the
putative inhibitory sites conferred a phenotype virtually
indistinguishable from wild type.
We next sought to determine if modulation of RLC
Ser1/Ser2/Thr9 phosphorylation could affect myosin II
assembly in non-mitotic cells. HeLa cells under normal
growth conditions that were expressing the RLC con-
structs were immunostained for MHC IIA (Figure 4A).
Relative to cells expressing wild type RLC, cells expres-
sing RLC-T18A/S19A displayed fewer stress fibers and
generally appeared larger, indicating a possible defect in
myosin II assembly and contractility (Figure 4A, column
1&2). In contrast, cells expressing RLC-T18D/S19D
appeared to have enhanced myosin II assembly in stress
fibers (Figure 4A, column 3). MHC IIA assembly in cells
expressing RLC-4D or RLC-4A, which might be pre-
dicted to cause an under-assembly or over-assembly
defect, respectively, was indistinguishable from the wild
type (Figure 4A, columns 4&5).
To quantitate assembly levels of myosin II when dif-
ferent RLC constructs were expressed, we used triton-
insoluble fractionation to separate cytoskeletal and cyto-
solic cellular fractions. Expression of RLC-T18D/S19D
resulted in an increase in assembled myosin II (Figure
4B). Expression of RLC-T18A/S19A, RLC-4A and RLC-
4D did not significantly alter resting assembly levels
Figure 3 Analysis of furrow ingression and multinucleation. (A) HeLa cells expressing the indicated RLC construct were imaged throughout
cell division. Furrow width was measured every 30 seconds for a minimum of 5 cells. Data are mean +/- SEM. * indicates p = <0.05. (B) HeLa
cells expressing the indicated RLC construct or treated with 60 uM blebbistatin for 24 hours were analyzed for nucleation state using propidium
iodide and flow cytometry. Black bars represent cells with DNA content of less than 4n. Grey bars represent cells with DNA content of 4n or
greater.
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Page 5 of 10Figure 4 MHC IIA assembly in resting and spreading cells. (A) HeLa cells in normal growth conditions expressing the indicated RLC-GFP
construct (green) were fixed and immunostained for MHC IIA (red). (B) Triton-insoluble fractionation was performed on HeLa cells in normal
growth conditions ("resting”) or actively spreading for 1 hr. Data are mean +/- SEM. N ≥ 6 for resting and N ≥ 9 for spreading. # indicates p = <
0.05 relative to the same cells in resting conditions. * indicates p = < 0.05 relative to the wild type RLC in the same conditions. (C) Multiple
pellet (P) fractions from the triton-insoluble fractionation studies were assayed for their Thr18/Ser19 phosphorylation levels. GFP was used to
show that each pellet contains similar amounts of the indicated RLC-GFP construct.
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forcing the cells to disassemble and reassemble their
cytoskeleton might reveal a role for RLC Ser1/Ser2/
Thr9 phosphorylation, we trypsin-collected the cells and
re-plated on fibronectin coated dishes for 1 hour before
performing triton-insoluble fractionation. Consistent
with RLC phosphorylation increasing at Thr18/Ser19
during cell spreading [13], we observed that in cells
expressing wild type RLC-GFP, myosin II assembly
levels increased during cell spreading (Figure 4B, com-
pare RLC in resting versus spreading). Expression of
RLC-T18A/S19A resulted in myosin II that fails to sig-
nificantly increase assembly level during spreading and
remained at a similar assembly level to non-spreading
cells (Figure 4B). These cells often show aberrant mor-
phology during spreading (data not shown), suggesting
that proper myosin II activation and/or assembly are
needed for proper cell spreading. Myosin II in cells
expressing RLC-T18D/S19D remains at elevated assem-
bly levels during spreading (Figure 4B). Therefore, sub-
stitution of unphosphorylatable or phosphomimetic
residues at the T18/S19 activating sites cause myosin II
to under-assemble or over-assemble, respectively, during
cell spreading. This is consistent with Thr18/Ser19
phosphorylation being a dominant mechanism regulat-
ing myosin II assembly. In contrast, in cells expressing
RLC-4A or RLC-4D, myosin II assembly levels increased
during spreading similar to the behavior of wild type
RLC (Figure 4B). This data is inconsistent with RLC
Ser1/Ser2/Thr9 phosphorylation significantly regulating
myosin II assembly levels during cell spreading.
In multiple assays performed in this work the RLC-4D
construct conferred a phenotype opposite of what
would be expected by the current model. Namely, RLC-
4D caused an over-assembly of MHC IIA in the furrow
(Figure 2C and 2D) and RLC-4D appeared to cause a
slight over-assembly of MHCIIA in resting cells (Figure
4B). To determine if Thr18/Ser19 phosphorylation was
altered when RLC-4D was expressed we performed wes-
tern blotting on the cytoskeletal fractions used for ana-
lysis in Figure 4B. Relative to both the wild type RLC-
GFP and RLC-4A constructs, expression of RLC-4D
caused a substantial increase in Thr18/Ser19 phosphor-
ylation (Figure 4C). This result is once again inconsis-
tent with the model that Ser1/Ser2/Thr9
phosphorylation is inhibitory towards assembly. We
speculate that addition of multiple aspartate residues to
the N-terminus of the RLC might be inhibiting 10S for-
mation, possibly leaving the RLC more susceptible to
the activation kinases. Alternatively, it is possible that
addition of these aspartate residues inhibits interaction
between the RLC and potential phosphatases. Clearly,
further studies are needed to resolve this unexpected
result.
Recent work by the Sellers lab has shown that despite
some minor differences, heavy meromyosin (HMM)
molecules with GFP-tagged RLC constructs can be regu-
lated via phosphorylation in a similar manner to myosin
molecules with untagged RLC [14]. Although this work
by Kengyel and colleagues analyzed an N-terminal GFP
fusion (in contrast to our C-terminal GFP fusion), their
studies show that a GFP-tagged RLC can associate with
myosin heavy chains and behave relatively normal.
Additionally, our studies show that cells expressing the
wild type RLC-GFP behave normal during cytokinesis
(Figure 3) and during adhesion-stimulated filament
assembly (Figure 4B). In conjunction with our IP data
(Figure 2B) suggesting a substantial replacement of the
endogenous RLC on the myosin II population, this data
argues strongly for both normal association and function
for the RLC-GFP used in these studies.
Due to the remaining presence of a small level of
endogenous RLC in these cells, we cannot entirely rule
out a role for RLC Ser1/Ser2/Thr9 phosphorylation in
regulating myosin II in our system. However, it is
important to note that each of the assays performed
here, with the exception of assessing a failure to com-
plete cytokinesis by measuring nucleation state, demon-
strate that point mutations at Thr18/Ser19 significantly
alter myosin II function in live cells. Therefore, the
RLC-T18/S19 constructs help to establish each assay as
a valid method to investigate the magnitude of the role
of Ser1/Ser2/Thr9 phosphorylation. Collectively, these
assays show that even in the presence of a small amount
of endogenous RLC, RLC-T18/S19 mutants display phe-
notypes congruous with the established model, while
RLC-4A and RLC-4D mutants display phenotypes simi-
lar to the wild type RLC. To completely eliminate the
possibility that residual RLC is masking an effect of
Ser1/Ser2/Thr9 phosphorylation, future experiments
might utilize siRNA/shRNA approaches in conjunction
with resistant RLC constructs. This may help to more
conclusively determine any role for RLC Ser1/Ser2/Thr9
phosphorylation in live cells.
It is intriguing that expression of RLC-T18A/S19A
delayed furrow ingression but did not inhibit cytokinesis
in two different cell types. Again, it is possible that the
introduced RLC-GFP constructs are not fully displacing
the endogenous RLC from the MHC and therefore, the
small amount of residual wild type myosin II is enough
to drive division. Alternatively, it is possible that basal
levels of myosin II ATPase, even in the absence of
Thr18/Ser19 phosphorylation, are sufficient to drive fur-
row contraction. Future experiments may differentiate
between these possibilities.
In addition to MLCK, RLC can also be phosphorylated
at Thr18/Ser19 by a number of other kinases, including
citron kinase [15], Rho-kinase [16], ZIPkinase [17] and
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http://www.biomedcentral.com/1471-2121/12/52
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interact with and phosphorylate RLC following PKC
phosphorylation was MLCK. Also, the dominant myosin
phosphatase at Thr18/Ser19 in most cells consists of
PP1cδ and myosin phosphatases target subunit (MYPT)
[18]. This phosphatase has also not been tested for its
ability to interact with and dephosphorylate RLC follow-
ing PKC phosphorylation. Therefore, RLC phosphoryla-
tion at Thr18/Ser19 is controlled by a number of
different regulators, but only one of those, MLCK, has
been tested for its efficacy following Ser1/Ser2/Thr9
phosphorylation. It is possible that the ability of the
other kinases or phosphatase to phosphorylate or
dephosphorylate RLC at Thr18/Ser19 is not affected by
Ser1/Ser2/Thr9 phosphorylation. If this scenario were
true then it would prescribe two additional possibilities.
First, the activity of the other kinases or inhibition of
the phosphatase may be compensating for abrogated
MLCK activity following Ser1/Ser2/Thr9 phosphoryla-
tion in live cells. Second, processes that are highly
dependent on MLCK phosphorylation of RLC may be
more susceptible to modulation by Ser1/Ser2/Thr9
phosphorylation. Future experiments should investigate
the effect of Ser1/Ser2/Thr9 phosphorylation on the
ability of other regulators of myosin II to interact with
and modulate myosin II activity. Additionally, future
experiments investigating alternative cell types or alter-
native cellular processes, especially those that are MLCK
d e p e n d e n t ,m a yy e tu n v e i lam o r es i g n i f i c a n tr o l ef o r
Ser1/Ser2/Thr9 phosphorylation in live cells.
Conclusions
The data presented here argues that RLC Ser1/Ser2/
Thr9 phosphorylation does not significantly regulate
myosin II assembly during cytokinesis and cell spreading
in HeLa cells. These studies further reinforce the impor-
tance of RLC Thr18/Ser19 phosphorylation on myosin
II assembly and suggest that alternative mechanisms of
disassembling myosin, such as RLC Thr18/Ser19 de-
phosphorylation, MHC phosphorylation [19,20] and
Mts1 binding [21], are more relevant in live cells.
Methods
Cell Culture
HeLa Tet-OFF were a kind gift of Bob Adelstein and
were maintained in MEM with 10% fetal bovine serum
and 1% penicillin/streptomycin. Polyclonal stable cell
lines were created by transfecting 1 ug plasmid DNA
into HeLa Tet-OFF using the Lonza Nucleofector (solu-
tion kit R, program I-13). Cells were selected in 300
mg/ml hygromycin and maintained in 1 ug/ml doxycy-
cline. Approximately 20-100 colonies were pooled for
each cell line. To identify responsive cells, Doxycycline
(Sigma) was removed from the media for 2-3 days and
GFP positive cells were isolated using flow cytometry.
These cells were immediately placed back in doxycycline
and stock cultures were maintained in Doxycycline
throughout culturing. Cells were cultured in doxycy-
cline-free media for 2-4 days prior to performing experi-
ments. Primary human keratinocytes were isolated from
discarded, de-identified human neonatal foreskins as
previously described [22]. These were obtained from
University Hospitals Rainbow Babies and Children’s
Hospital (Cleveland, OH) following approval from the
University Hospitals Internal Review Board (material
transfer #UNI-37894). The keratinocytes were main-
tained in keratinocyte serum-free medium (Gibco, Invi-
trogen Cell Culture).
Creation of RLC mutants
The plasmid pTRE-GFP was a kind gift of Bob Adelstein
and was created as previously described [23]. pTRE-GFP
was modified to introduce a BamH1 restriction site
immediately upstream of Age1 to create the vector
pTRE3-GFP. MRLC2 cDNA (gene MYL12B; gene ID
103910) was purchased from ATCC. BamH1 and Age1
restriction sites were introduced at the 5’ end and 3’
end, respectively, of the RLC cDNA using PCR. This
PCR product was then ligated into the pTRE3-GFP vec-
tor using the BamH1 and Age1 sites to create pTRE3-
RLC-GFP that expresses the RLC protein with the EGFP
reporter at the C-terminal end. pTRE3-RLC-GFP-4A
and pTRE3-RLC-GFP-4D constructs were created using
standard PCR mutagenesis techniques followed by liga-
tion into pTRE3-GFP using the BamH1 and Age1 sites.
For RLC-T18A/S19A and RLC-T18D/S19D, dsDNA oli-
gonucleotides were purchased from DNA2.0 with the
desired point mutations, a 5’ BamH1 site and 3’ Xma1
site. These were then digested and ligated into pTre3-
RLC-GFP using BamH1 and Xma1 sites to create
pTRE3-RLC-GFP-T18A/S19A and pTRE3-RLC-GFP-
T18D/S19D. All DNA segments subjected to PCR were
sequenced to confirm absence of PCR-generated errors.
Western Blotting and Immunoprecipitation
For western blotting the following antibodies were used:
GFP, (Invitrogen catalog #A6455), MHC IIA (Biomedi-
cal Technologies catalog #BT-567), RLC (Proteintech
Group catalog #10324-1-AP), RLC T18-P/S19-P (Cell
Signaling catalog #3674S).
For immunoprecipitation myosin IIA antibody
(Abcam; catalog #A55456) was pre-incubated with Pro-
teinG Dynabeads (catalog #100.03D). Cells were lysed in
lysis buffer (20 mM Tris pH 7.5, 1% Triton X-100, 10%
glycerol, 250 mM NaCl, 2 mM EDTA, 25 mM b-glycer-
ophosphate, phosphatase inhibitor cocktail 2 and 3
(Sigma; catalog #P5726 and #P0044) and protease inhi-
bitor cocktail (Sigma; catalog #P8340). The lysate was
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complex. Following 3 washes in lysis buffer, the bound
protein was eluted directly in 2× sample buffer supple-
mented with protease and phosphatase inhibitor
cocktails.
Immunofluorescence
Fixation and immunostaining was performed as pre-
viously described [24], except that primary antibodies
were incubated overnight at 4°C. The following antibo-
dies were used: GFP (Invitrogen, A-6455), RLC (Protein-
tech Group, 10324-1-AP), RLC S1-P (ECM Biosciences,
MP3461), MHC IIA (Sigma, M8064). Samples were
mounted in Vectashield (Vector Laboratories, H-1200).
Images were acquired on a Leica TCS-SP2 with a plan-
apochromat 63x/1.4 NA oil objective.
Myosin II furrow recruitment
Following fixation and immunostaining for MHC IIA, a
single confocal image was taken of anaphase cells at a z-
position corresponding to their greatest length. Using
ImageJ, a single 10 pixel-wide line was drawn through
the contractile ring spanning both sides of the cell. Cor-
tical myosin II was defined as the mean of the two peak
intensities in the line histogram. Cytoplasmic myosin II
was defined as a mean of the intensities between those
peaks. The cortical to cytoplasmic ratio was used for
comparative analysis.
Furrow ingression
Mitotic cells were collected using the shake-off method.
These cells were replated on tissue culture dishes pre-
treated with 20 ug/ml fibronectin (Sigma-Aldrich,
F1141). Images were collected every 15 seconds using a
Leica DMIRE2 with a plan 20x/0.4 NA objective. Furrow
to furrow distance was measured using the line draw
tool in ImageJ.
Nucleation state analysis
Cells were analyzed for their nucleation state using pro-
pidium iodide as previously described [24]. Only GFP-
positive cells were analyzed.
Triton-insoluble fractionation
Cells under normal growth conditions or actively
spreading for 1 hr on fibronectin coated tissue culture
dishes were lysed in TIF buffer (50 mM Tris-HCl, pH
7.4, 5 mM NaCl, 140 mM potassium-acetate, 0.6% Tri-
ton X-100, 1 mM EDTA, 5 mM EGTA, 5 mM DTT
and protease/phosphatases inhibitors). Soluble and inso-
luble fractions were separated by centrifugation at 8,000
× g for 15 min. The soluble supernatant was removed
and combined with an equal volume 2× Laemmli sam-
ple buffer. The pellet was resuspended in the same
amount of 2× Laemmli sample buffer as the superna-
tant, followed by dilution with an equivalent amount of
TIF buffer. Samples were boiled for 3 minutes and soni-
cated briefly prior to being subject to western blot ana-
lysis. Western blot band intensities were quantitated
using ImageJ.
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